Login to Your Account


Rare epidermolysis bullosa phase III in progress
Amicus Therapeutics Inc. CEO John Crowley told BioWorld Today his firm won't be the only company working on a therapy for the rare skin disorder epidermolysis bullosa, but the potential $847 million takeover of privately held Scioderm Inc. to bring aboard phase III Zorblisa means a handsome lead over the competition. more »

Our Habitat for All Things Science
No brainer: FTO's effects on weight are peripheral effect

In genomewide association studies (GWAS), a variant in the gene FTO is the strongest obesity-correlated signal in the human genome.

Since it was first flagged by GWAS seven years ago, though, why FTO is so strongly linked to obesity has remained a puzzle.

Now, scientists have dissected the cellular circuitry that is affected by FTO. Their work both suggests new obesity targets and could serve as a general roadmap for how to understand the effects of variants in noncoding regions of the genome.

READ MORE »